Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Medacta : 2021 Half-Year Report

09/10/2021 | 01:12am EDT

H A L F - Y E A R R E P O R T 2 0 2 1

L O O K B E Y O N D T H E O R D I N A R Y

2

MEDACTA AT A GLANCE

Medacta is an international company specializing in the design, production, and distribution of innovative orthopedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.

3

From minimally invasive surgery to

Personalized Medicine and beyond

4

TABLE OF CONTENTS

3

MEDACTA AT A GLANCE

HIGHLIGHTS FIRST HALF 2021

6

SHARE INFORMATION

8

LETTER TO SHAREHOLDERS

10

ALTERNATIVE PERFORMANCE MEASURES

12

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021

17

1.

INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS FOR THE PERIODS ENDED JUNE 30, 2021 AND 2020

18

2.

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIODS ENDED JUNE 30, 2021 AND 2020

19

3.

INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION FOR THE PERIODS ENDED JUNE 30, 2021 AND DECEMBER 31, 2020

20

4.

INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIODS ENDED JUNE 30, 2021 AND 2020

21

5.

INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE PERIODS ENDED JUNE 30, 2021 AND 2020

22

6.

SELECTED EXPLANATORY NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

23

7.

INDIPENDENT AUDITOR'S REPORT

34

INVESTOR CALENDAR

35

CONTACTS

38

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Medacta Group SA published this content on 10 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 September 2021 05:11:01 UTC.


© Publicnow 2021
All news about MEDACTA GROUP SA
10/19MEDACTA : extends the personalized medicine concept to total knee revision surgeries with ..
PU
10/19Medacta extends the personalized medicine concept to total knee revision surgeries with..
DJ
10/19Medacta Extends the Personalized Medicine Concept to Total Knee Revision Surgeries with..
CI
09/29MEDACTA : First Surgery with Medacta's Minimally Invasive M.U.S.T. MC Platform Read More >
PU
09/29First Surgery with Medacta's Minimally Invasive M.U.S.T. MC Platform
DJ
09/16MEDACTA : celebrates the milestone of 10,000 Medacta Shoulder System implanted worldwide!
PU
09/14MEDACTA : Credit Suisse Lifts Price Target on Medacta Group, Maintains Neutral Recommendat..
MT
09/10MEDACTA : Swiss Medical Device Maker Medacta's H1 Profit Climbs as All Business Areas Expa..
MT
09/10MEDACTA : Press Release – 2021 Half-Year Results
PU
09/10MEDACTA : reports strong profitability with 31.9% adjusted EBITDA margin in the first seme..
PU
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2021 357 M 415 M 415 M
Net income 2021 56,0 M 65,1 M 65,1 M
Net Debt 2021 93,3 M 108 M 108 M
P/E ratio 2021 53,5x
Yield 2021 0,48%
Capitalization 2 980 M 3 455 M 3 462 M
EV / Sales 2021 8,61x
EV / Sales 2022 7,48x
Nbr of Employees 1 246
Free-Float 30,5%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MOVE | CH0468525222 | MarketScreener
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 149,00 €
Average target price 111,67 €
Spread / Average Target -25,1%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA81.51%3 455
ABBOTT LABORATORIES17.02%227 151
MEDTRONIC PLC5.90%166 948
BECTON, DICKINSON AND COMPANY-1.55%70 749
HOYA CORPORATION21.09%55 803
DEXCOM, INC.52.99%54 725